Client Resources

: Press releases; MedImpact receives three-year NCQA reaccreditation.; Commitment to high quality standards and rigorous process assessment results in 100% score; READ MORE

: Press releases; MedImpact’s Managed Care Residency Program Receives 8-year Accreditation.; After extensive evaluation, the American Society of Health-System Pharmacists accredits MedImpact’s program for full term; READ MORE

: Press releases; MedImpact celebrates 30 years making pharmacy benefits transparent, understandable, and affordable.; At a time of rapid vertical integration in the industry, MedImpact remains independent and member-focused; READ MORE

: Client news; MedImpact leverages advanced technology and network solutions to improve member experience and reduce costs for our pharmacy partners.; The U.S. spends more per capita on healthcare than any other country in the world, but it has a high prevalence of diabetes, worse cardiovascular outcomes and lower life expectancy compared to other high-income countries.1 U.S. healthcare costs reached $3.6 trillion in 2018 and spending is anticipated to soar to nearly $6 trillion by 2027.2 However, the U.S. ranks poorly in health system performance.3; READ MORE

: Client news; NY Attorney General recognizes MedImpact for assisting in multimillion dollar medicaid FWA investigation.; Fraud, waste, and abuse (FWA) is a national crisis that costs our healthcare system at least $200 billion every year. Even worse, research suggests that only a mere 5% of these losses are recovered.1; READ MORE

: Client news; The hazards of auto-refills.; MedImpact helps reduce waste and oversupply with flexible auto-refill strategies.; READ MORE

: Client news; Annual drug trend report looks at Medicare brand and generic drug trends.; Breaking news of the White House’s consideration of a sweeping executive order that could cut prices on brand-name prescription drugs sold to Medicare and other government programs continues to top this week’s healthcare headlines.; READ MORE

: Client news; Investigating top diabetes trends by lines of business.; Diabetes spending will continue to increase as new pipeline agents like oral semaglutide enter the market. For now, insulin still dominates the diabetes therapeutic class, accounting for 49% of market share. Newer generation, non-insulin products, like DPP4, SGLT2 or GLP-1s, or combinations that contain them, now make up a combined 50% of market share.; READ MORE

: Client news; MedImpact investigates the impact of oral semaglutide and diabetes market trends.; With the potential to change the landscape of diabetes treatment, oral semaglutide ushers in the next generation of diabetes care with its anticipated FDA approval in September.; READ MORE

Resources.